July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.
A new CDC study suggests that many urgent care centers in the U.S. still need to be made aware of pre-exposure prophylaxis and how to provide it.
However, a number of leading clinicians argue that the results should not deter care providers from prescribing PrEP for patients who are most at risk for HIV.
Some have expressed concern that, as PrEP use increases in the U.S., so will the transmission of other STIs. A new study pushes back against that worry.
In an era of HIV biomedical prevention and undetectable equals untransmittable (U=U), the primacy of condom use has changed, but the need to consider approaches to decrease STIs has not.
A substudy of the high-profile French PrEP study IPERGAY has reported alarmingly high rates of human papillomavirus (HPV) infection in HIV-negative gay men.
To gain a better understanding of the long-term effects of STI risk among PrEP users, researchers have developed a sophisticated computer simulation that can model changes in sexual behavior, PrEP adherence, STI screening and treatment and the impact...
Critics have been warning since the concept of oral PrEP was in its infancy that it would lead to major increases in condomless sex among users and a corresponding dramatic spike in STIs. So far, the data has been inconclusive.
"Current CDC guidelines may miss a significant number of asymptomatic STIs among PrEP users," researchers concluded, suggesting that STI screening may be warranted at each three-monthly visit.
How do providers, who see clients every three months for sexual health screenings and STI testing, talk to their clients about condom use, STIs and navigating the complicated landscape of safer sex?